New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show - ABC News - Breaking News, Latest News and Videos

{
  "signal_id": "0dca11c2-a862-b6bf-3801-8b86f01cc900",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-08T16:47:15+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://abcnews.com/Health/new-drug-shows-promise-reducing-copd-symptoms-smokers/story?id=136257253",
    "title": "New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show - ABC News - Breaking News, Latest News and Videos",
    "excerpt": "A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former and current smokers, according to results from late-stage clinical trials. The medication, called tozorakimab and developed by AstraZeneca, is the first biologic drug to show efficacy in treating COPD symptoms in a broad population of patients with varying ranges of blood eosinophil counts, according to Dr. Frank Sciurba, professor of pulmonary and critical care medicine at the University of Pittsburgh, in an AstraZeneca press release. The measurement of eosinophil levels in the blood can help guide optimal choices of inhaler regimens for COPD treatment, based on guidelines published by the Gold Initiative for Chronic Obstructive Lung Disease . There are already some Food and Drug Administration-approved medications for COPD in patients with elevated blood eosinophil counts, but if approved, tozorakimab would become a potential first biologic option for COPD patients with lower eosinophil counts. The results were presented at the European Respiratory Society Congress conference on Tuesday and set to be published in a peer-reviewed journal. Patients taking inhaler regimens for COPD management, which is the current standard of care, were randomized to receive either 300 milligrams of tozorakimab once every four weeks via injection or a placebo in two separate...",
    "product": "tozorakimab",
    "summary": "AstraZeneca is developing tozorakimab, a first-in-class monoclonal antibody, which has shown promise in late-stage clinical trials for reducing COPD symptoms in smokers and former smokers.",
    "planning": true,
    "image_url": "https://i.abcnewsfe.com/a/94f5d470-92ec-415e-9f9a-f8a7dfce128d/AstraZeneca-gty-er-260907_1788811210103_hpMain_16x9.jpg?w=1600",
    "confidence": 0.9,
    "product_data": {
      "name": "tozorakimab",
      "full_text": "The medication, called tozorakimab",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-08T16:47:15Z",
    "article_sentence": "The medication, called tozorakimab and developed by AstraZeneca, is the first biologic drug to show efficacy in treating COPD symptoms in a broad population of patients with varying ranges of blood eosinophil counts, according to Dr. Frank Sciurba, professor of pulmonary and critical care medicine at the University of Pittsburgh, in an AstraZeneca press release."
  }
}

curl https://signals.autobound.ai/v1/signals/0dca11c2-a862-b6bf-3801-8b86f01cc900 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'